leadf
logo-loader
viewImugene Ltd

Imugene managing director acquires 27 million shares via exercise of options

Last month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.

Imugene Ltd - Imugene managing director acquires 27 million via exercise of options
The PD1-Vaxx trial will involve patients with non-small cell lung cancer

Imugene Limited's (ASX:IMU) chief executive officer and managing director Leslie Chong has exercised 27 million options at an exercise price of $405,000.

Chong now holds a significant personal investment of more than 31 million shares and +50 million options in the company.

Last month, Imugene received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.

Ethics approval is confirmation that Imugene has completed all necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to begin human clinical trials.

Involving non-small cell lung cancer patients

The first-in-human, Phase-1 multi-centre dose-escalation study of PD1-Vaxx will involve patients with non-small cell lung cancer.

Medical investigators will test different doses of PD1-Vaxx as a monotherapy and in combination with immune checkpoint inhibitor drugs.

The primary aim of the Phase-1 trial is to determine safety and an optimal biological dose as a monotherapy and later in combination with immune checkpoint inhibitors.

Quick facts: Imugene Ltd

Price: 0.047 AUD

ASX:IMU
Market: ASX
Market Cap: $211.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

on 20/7/20

2 min read